Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

ss R&D associated with the license discussed below for Clonidine Topical Gel from Arcion Therapeutics (Arcion).

In addition to clinical development activities, BDSI also made an important stride forward in building its pipeline of products for the treatment of pain with the acquisition of patented Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).  BDSI entered into a worldwide licensing agreement with privately held Arcion, where BDSI will develop and commercialize Clonidine Topical Gel. 

The effectiveness of Clonidine Topical Gel was previously assessed in reducing pain in PDN in a double-blind, placebo-controlled, Phase 2 study.  A significant treatment difference was seen in the pain intensity (p=0.01, n=63) in the planned subset analysis of diabetic patients who had documented evidence of functioning pain receptors in the skin of the lower leg.  At a minimum, this supports its effectiveness in diabetic patients with functioning pain receptors in the skin which accounts for approximately one-third to one-half of the nearly 26 million people that according to the American Diabetes Association are suffering from PDN.  BDSI plans to prepare for a confirmatory study in the latter part of 2013 which could lead to data availability by the end of 2014.  The PDN market is highly under-served by existing products, such as the oral medications Lyrica and Cymbalta.  BDSI estimates annual peak sales potential for the product in excess of $300 million in the U.S.

Under terms of the agreement, BDSI made an upfront payment of $2 million to Arcion in the form of unregistered shares of BDSI common stock.  No further milestone payments are due to Arcion until successful completion of the clinical development program and the filing of a New Drug Application (NDA). 

"BDSI continues to make remarkable progress in advancing its pipeline of BEMA products, BUNAVAIL and BEMA Bupren
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Service™
10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... , May 29, 2015 In recent years, ... availability of Big Data that can generate valuable insights. ... with utilizing Big Data have caused the biopharmaceutical sector ... industries. According to a recent study ... already have a Big Data team or function in ...
(Date:5/29/2015)... 29, 2015 GeneWEAVE, Inc ... (MDROs), announced that initial feasibility data supporting the ... and susceptibility testing from positive blood cultures will ... 31, 2015 in New Orleans, LA. The Company’s ... diagnostics that can quickly detect bacteria and assess ...
(Date:5/29/2015)... -- Asthma treatment could   see ... treatments enter arena, says   GBI Research ... several of the leading asthma brands, such as Advair ... the global market for asthma treatment is set to ...   New analysis from business intelligence provider ...
Breaking Biology Technology:Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3
... Supports Further ... Clinical Development of tgAAC94, BOSTON and SEATTLE, May ... news release earlier today, entitled,"Targeted Genetics Reports Additional Data From ... 1/2,clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin,Anklesaria, ...
... the increasing,challenges to patent protection and new product ... grow their pipelines.,With the increasing merger and acquisition ... integration of assets to be key in obtaining,value ... Integration,Excellence: What Bio- Pharma Companies Need to Know." ...
... U.S. cancer conference, CHICAGO, May 30 ... field of molecular diagnostics, announced today that data,from ... test,will be presented at the American Society of ... that MammaPrint, a,prognostic test for breast cancer recurrence ...
Cached Biology Technology:Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 2MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 3MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 4
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... KINGSTON, R.I. July 23, 2009 News reports ... by large numbers of Humboldt,s or jumbo squid have raised ... As a leading expert on the species who has ... and says the squid,s man-eating reputation is seriously overblown. ...
... study released online on July 22 in the journal ... researchers at Arizona State University and Princeton University show ... our multimodal, egg-headed, tool-using, bipedal, opposing-thumbed selves. ... "stupider" than ants. Humans and animals simply often make ...
... Texas Medical Branch at Galveston have identified women who are ... commonly known as Depo-Provera or the birth control shot. These ... will gain weight and will help physicians to counsel patients ... within the first six months of use, called "early gainers," ...
Cached Biology News:URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 2URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 3Ants more rational than humans 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2
... Histone Deacetylase (HDAC) Antibody Sampler Kit ... (HDAC1) Antibody, Catalog #2062, 40 ul Histone ... ul Histone Deacetylase 4 (HDAC4) Antibody, Catalog ... Antibody, Catalog #2082, 40 ul Histone Deacetylase ...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
Biology Products: